IL17A and myeloid sarcoma: Some authors reported a decrease in IL17-positive cells in MS patients on fingolimod 1.25 mg once daily at the long-term therapy stage, but not on IFNβ [8], while others reported an increase in IL17-producing cells in a considerable fraction of MS patients on fingolimod 0.5 mg once daily at the short-term treatment stage [9].